A股異動 | 濟民製藥(603222.SH)漲停 證券簡稱6月4日起變更為濟民醫療
格隆匯6月1日丨濟民製藥(603222.SH)盤初直線拉昇至漲停板,封單近15萬手。現報17.78元,成交額超2億元,總市值60.6億元。濟民製藥5月31日公吿,經公司申請,並經上交所辦理,公司證券簡稱自6月4日由“濟民製藥”變更為“濟民醫療”,公司證券全稱及公司證券代碼保持不變。在以“大健康產業”為主線,公司業務結構已逐步優化,目前醫療器械和醫療服務已成為公司收入及利潤的主要來源。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.